The mTOR inhibitor ridaforolimus has been studied in a phase II trial of patients with advanced bone sarcomas and this study revealed improved progression-free survival in advanced sarcomas including osteosarcoma [6]. The gene discussed is MTOR; the disease is osteosarcoma.